Fri, Oct 31, 2014, 6:16 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

BioCryst Pharmaceuticals, Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    anybody tried to go to a hospital lately...

    by huskys4u2 Oct 23, 2014 2:34 PM

    You been around Wood lately? Maybe not Ebola but I imagine he has some bugs somewhere.

  • Reply to

    FAILS TO DELIVER

    by mdaddy1234 Oct 23, 2014 1:31 PM

    They are not having any trouble with fails to deliver which was the point of my post. That implies to me that this is institutional trading...and not necessarily hedge funds. Now they may be allowing hedge funds to short with their blessing to either accumulate stock or keep a lid on the price. I don't know. I agree they can hold it without news. The question is why?

  • Reply to

    FAILS TO DELIVER

    by mdaddy1234 Oct 23, 2014 1:31 PM

    Well of coarse the shorting is institutional. Mostly hedge funds. Same as small E&Ps. Some day shorts are playing games between other Ebola stocks and the like, looking at the huge short interest as a guide or proxy, but this is long(er) term institutional.

    They shorted a whole basket of bios without an approved product or earnings after the summer run. I'm sure that some shorted everything in the index itself and they have been closing that in panic after this recovery which is why the index has been performing as it has. Hedgies are the only ones that could get MMs to accept the short without stock or risk losing their business.

    Us little guys are different. But we are moving into the time of the year where they need to cover everything. Today's buying is an example. They really want to cover before the $12.50 trigger or risk moving it a lot higher. Personally, I think they can hold it without news, but we will see.

    Sentiment: Buy

  • you have to sign a release that you haven't been to west africa, or been in contact with anybody who has at rush u in chicago...

  • Reply to

    FAILS TO DELIVER

    by mdaddy1234 Oct 23, 2014 1:31 PM

    Who is shorting this stock? I say it is institutions. Who else would hang 10 million shares in the wind? Short interest tomorrow.

  • 20140915|09058V103|BCRX|3059|BIOCRYST PHARMACEUTICALS INC|11.91

    20140916|09058V103|BCRX|3300|BIOCRYST PHARMACEUTICALS INC|11.45

    20140917|09058V103|BCRX|11853|BIOCRYST PHARMACEUTICALS INC|11.34

    20140918|09058V103|BCRX|5948|BIOCRYST PHARMACEUTICALS INC|11.30

    20140919|09058V103|BCRX|6820|BIOCRYST PHARMACEUTICALS INC|11.10

    20140922|09058V103|BCRX|59|BIOCRYST PHARMACEUTICALS INC|10.93

    20140923|09058V103|BCRX|152|BIOCRYST PHARMACEUTICALS INC|10.44

    20140924|09058V103|BCRX|24586|BIOCRYST PHARMACEUTICALS INC|10.22

    20140925|09058V103|BCRX|836|BIOCRYST PHARMACEUTICALS INC|11.29

    20140926: NONE

    20140929|09058V103|BCRX|869|BIOCRYST PHARMACEUTICALS INC|10.66

    20140930|09058V103|BCRX|5791|BIOCRYST PHARMACEUTICALS INC|10.49

  • Stonehouse said they are staying focused as a small molecule, rare disease company and that both IV P and 4430 are ways of avoiding dilution through govt. funding via stockpiling.

    However, BCRX is now in the limelight for 4430. IF NHP results come back as expected, this will bring greater expectation to safe human study and the broad spectrum growth potential of the drug...i.e., once proven safe the Animal Rule can be used to approve 4430 for other disease indications that aren't testable in human trials.

    ACCELERATED is the key word. EMA (Europe FDA) is pushing for data and companies to apply for orphan drug status: "Speeding up development of Ebola treatments and vaccines EMA encourages companies to apply for orphan designation"

    US govt. also accelerating ebola drugs through approval. This is a timeline game changer for BCRX in regards to potential size of US stockpile and ROW, especially as it is a broad spectrum antiviral showing indications towards ebola, Marburg, MERS, Dengue...20 filoviruses. Yes, it has to go through testing and approval (like every biotech pre-approved drug) but BCRX has more global interest in the potential of 4430.

    BCRX may not be an "ebola" company, but the new awareness isn't going to hurt...welcome all...now go and listen to some of the recent conference calls to learn more about the company.

  • Reply to

    NIH Meeting: Oct. 22: BCRX

    by maphere Oct 20, 2014 10:27 AM

    dinepat, you just earned the ignore status…

  • "So, odds are that 4430 has been used in one of them. The only one who still has ebola remaining is Pham. Tekmire was used in Nebraska. Zmapp in Doc Kent Brantly and Nancy Writebol. Vinson and Pham ??"

    Sounds a lot like that post you wrote suggesting HAE patients could have died in the trial before the results were released. Nice Jacki (I've emasculated with you by adding the "i" at the end - you've earned it, with some of your terrible calls here!).

  • Reply to

    NIH Meeting: Oct. 22: BCRX

    by maphere Oct 20, 2014 10:27 AM

    Wait a minute... this is from the PR where they were given the funding back in late Aug.

  • Reply to

    NIH Meeting: Oct. 22: BCRX

    by maphere Oct 20, 2014 10:27 AM

    That's because BCRX isn't about Ebola MOMO - it went up on HAE and institutional buying via the secondary. Anyone who tells you otherwise is short or has a personal vendetta with Yahoo message board posters (LOL!).

  • Reply to

    NIH Meeting: Oct. 22: BCRX

    by maphere Oct 20, 2014 10:27 AM

    Having said that, we are up 6% whilst TKMR and NLNK are down and IBIO is tanking.

  • Reply to

    NIH Meeting: Oct. 22: BCRX

    by maphere Oct 20, 2014 10:27 AM

    This is an annoyingly vague – it could be read that the efficacy study is completed, or rather that the next step would be the completion of the study. I think it means the latter...

    "The successful completion of an efficacy study in an experimental Ebola virus disease model in non-human primates represents an important next step towards understanding the potential of BCX4430 as a treatment for Ebola disease in humans."

  • Reply to

    NIH Meeting: Oct. 22: BCRX

    by maphere Oct 20, 2014 10:27 AM

    thanks map, even though BCRX doesn't want to give the "blow-by-blow" they should put out a pr for a…

    "successful completion of an efficacy study in an experimental Ebola virus disease model in non-human primates"

    after all, this is material to the company.

  • Reply to

    NIH Meeting: Oct. 22: BCRX

    by maphere Oct 20, 2014 10:27 AM

    No one's talking. It's never been so non-responsive on their end.

    If 4430 was used experimentally (Emory and Dallas nurse) then maybe that gets included with IND.

    Multiple big announcements coming from BCRX, not sure which direction they'll come from first...I suspect NHP results first, IV P approval second and HAE trial 3rd.

  • Reply to

    NIH Meeting: Oct. 22: BCRX

    by maphere Oct 20, 2014 10:27 AM

    map, can we get some clarification on this?

  • Reply to

    NIH Meeting: Oct. 22: BCRX

    by maphere Oct 20, 2014 10:27 AM

    "The successful completion of an efficacy study in an experimental Ebola virus disease model in non-human primates represents an important next step towards understanding the potential of BCX4430 as a treatment for Ebola disease in humans."

    so the monkeys lived?

    IND next?

  • Reply to

    NIH Meeting: Oct. 22: BCRX

    by maphere Oct 20, 2014 10:27 AM

    The successful completion of an efficacy study in an experimental Ebola virus disease model in non-human primates represents an important next step towards understanding the potential of BCX4430 as a treatment for Ebola disease in humans. NIAID, part of the National Institutes of Health, granted a contract to BioCryst in September 2013 valued up to $22.0 million over five years. With this additional award, the BCX4430 development contract has been increased in value to $24.4 million, if all options are exercised.

    This project will be funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300017C

  • Reply to

    NIH Meeting: Oct. 22: BCRX

    by maphere Oct 20, 2014 10:27 AM

    NIH further update on Primate Study of BCX4430 in Ebola and Progress of Ebola Treatments and Vaccines ?

  • Reply to

    NIH Meeting: Oct. 22: BCRX

    by maphere Oct 20, 2014 10:27 AM

    NIAID is supporting the development of potential treatments is BCX4430, a drug that BioCryst Pharmaceuticals .

    The lead BSAV compound is BCX4430, an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.
    BCRX is developing BCX4430 in collaboration with U.S. Government Agencies following the Animal Rule regulatory pathway.
    BCRX designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases.

BCRX
11.72-0.34(-2.82%)Oct 31 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.